Welcome to our dedicated page for Dianthus Therapeutics /DE/ SEC filings (Ticker: DNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Dianthus Therapeutics /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Dianthus Therapeutics /DE/'s regulatory disclosures and financial reporting.
Dianthus Therapeutics director Paula Soteropoulos exercised stock options and sold the resulting shares. On March 31, 2026, she exercised options for 599 shares of common stock at $8.44 per share and immediately sold all 599 shares at $80.11 per share in an open-market transaction.
The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025. Following the sale, the filing shows 0 common shares held directly from this transaction.
Insider notice of planned sale and recent 10b5-1 disposals. The filing reports 1,198 shares of Common Stock to be sold on 03/31/2026 following an exercise of stock options for cash. It also discloses 10b5-1 sales completed on 03/24/2026 totaling 27,594 shares for $2,153,579.25.
Dianthus Therapeutics director Paula Soteropoulos exercised stock options for 27,594 shares of common stock at an exercise price of $8.44 per share and immediately sold the same 27,594 shares in an open-market transaction at $78.05 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025. Following the sale, she held no shares of common stock directly.
Dianthus Therapeutics reports that in the first quarter of 2026 it proposed, and in March 2026 received, written FDA agreement to three changes across all ongoing and planned claseprubart trials. Anti-nuclear antibodies will no longer be used as a screening criterion or routinely tested, and the hypothetical safety risk is reclassified from systemic lupus erythematosus to drug-induced lupus. The company notes there have been no cases of SLE or DIL in any claseprubart program to date.
Dianthus’ investor presentation highlights claseprubart and DNTH212 as pipeline-in-a-product autoimmune therapies, with strong Phase 2 gMG data, an early Phase 3 CIDP “GO” decision, and broad neuromuscular and autoimmune indications under study. The company cites a strong financial position with approximately $1.2 billion of pro forma cash and runway expected into 2030, supporting multiple planned milestones, including a Phase 3 gMG trial initiation, Phase 2 MMN data, CAPTIVATE Part B readout guidance in CIDP, and Phase 1 top-line results for DNTH212.
Dianthus Therapeutics CEO and President Garcia Marino exercised stock options on March 16, 2026 to acquire a total of 65,292 shares of common stock. This came from options for 59,700 shares at $6.70 per share and 5,592 shares at $17.88 per share. Following these exercises, Marino holds 65,292 common shares directly, while some option awards continue to vest over time according to their original schedules.
Dianthus Therapeutics CEO Garcia Marino reported an option exercise and related share sales. On March 12, 2026, he exercised stock options for 122,918 shares of common stock at an exercise price of $6.70 per share. The same day, he sold 122,918 shares of common stock in multiple open-market transactions at prices ranging from about $80.69 to $85.53 per share. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on November 17, 2025. Following these transactions, he reported no directly held common shares and no remaining derivative position from this option grant.
Dianthus Therapeutics (DNTH) chief accounting officer Edward Carr exercised stock options and sold the resulting shares in a pre-planned series of trades. On March 12, 2026, he exercised options for 43,682 shares of common stock at exercise prices of $17.88, $21.77, and $22.07 per share.
The same day, he sold 43,682 common shares in multiple open-market transactions at weighted-average prices ranging from about $80.71 to $85.53 per share. A footnote states these sales were executed under a Rule 10b5-1 trading plan adopted on December 11, 2025, indicating the trades were pre-scheduled rather than opportunistic.
Dianthus Therapeutics EVP and Head of R&D Simrat Randhawa exercised stock options for 33,830 shares of common stock and sold 33,830 shares in an open-market transaction. The sale was executed at a price of $81.48 per share and made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025. Following these transactions, Randhawa held no shares of common stock directly, according to the filing.